Pieris Pharmaceuticals (Seite 2)
eröffnet am 06.01.17 13:11:27 von
neuester Beitrag 28.08.23 08:45:50 von
neuester Beitrag 28.08.23 08:45:50 von
Beiträge: 104
ID: 1.244.291
ID: 1.244.291
Aufrufe heute: 0
Gesamt: 11.896
Gesamt: 11.896
Aktive User: 0
ISIN: US7207951036 · WKN: A12G4Q · Symbol: PI6
0,1386
EUR
+1,61 %
+0,0022 EUR
Letzter Kurs 22.04.24 Tradegate
Neuigkeiten
22.08.23 · Sharedeals |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 53,50 | +98,15 | |
| 1,3500 | +29,82 | |
| 4,5700 | +24,18 | |
| 1,8300 | +23,65 | |
| 2,7800 | +22,47 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7603 | -15,56 | |
| 0,7008 | -15,56 | |
| 2,8600 | -19,21 | |
| 5,2000 | -27,78 | |
| 9,8500 | -32,12 |
Beitrag zu dieser Diskussion schreiben
Feedback
Gut, dass die Gap-Spekulation auch noch ein bisschen Substanz hat. BVF hat immerhin 20% der Aktien, bei whalewisdom stand sogar 25%. An EK sind noch 40 Mio da = 0,40 pS und Milestones könnten noch von Servier, Boston Pharma und Seagen kommen.
Eine Übernahme könnte ich mir bei der MK auch gut vorstellen.
Es gab schon riskantere Spekulationen.
Eine Übernahme könnte ich mir bei der MK auch gut vorstellen.
Es gab schon riskantere Spekulationen.
Knappe 40% haben wir bereits und ab 0,35 $ ist das Gap bis 0,90 $ offen - eine Menge Potenzial..
Der Trend ist sehr schön, sollte über mittlere Sicht 30%-60% bei stetigem Newsflow bringen. Es gibt ja einiges was demnächst berichtet werden könnte ✌️
Position gestartet
Trading Spotlight
17.7.
Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring
https://www.accesswire.com/768538/Pieris-Pharmaceuticals-Pro…
...
Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases and cancer, today provided a strategic update following recent events that have impacted its inhaled respiratory franchise, including AstraZeneca's discontinuation of enrollment of the Phase 2a study for elarekibep.
AstraZeneca has now informed the Company of its decision to terminate the parties' R&D collaboration agreement and hand back elarekibep along with discontinuing the remaining discovery program.
Pieris' management and board of directors have assessed several strategic options, which will include focusing on execution of new or expanded partnerships to advance its therapeutic programs, including cinrebafusp alfa (PRS-343), PRS-220 and PRS-400.
While it explores potential transactions, Pieris will prioritize capital preservation, with cash, cash equivalents and investments totaling approximately $54.9 million as of June 30, 2023. As part of its cash preservation plan, Pieris initiated a corporate restructuring that will result in a reduction of the Company's workforce by approximately 70%.
These and other cost-saving measures are expected to maximize the opportunity to pursue a range of transactions across both its respiratory and immuno-oncology franchises and its discovery platform. Pieris has retained Stifel, Nicolaus & Company, Inc. as its exclusive financial advisor to evaluate a range of strategic options.
These strategic options may include an acquisition, merger, reverse merger, other business combination, sale of assets, financing alternatives, licensing, or other strategic transactions involving the Company. There can be no assurance of a transaction, a successful outcome of these efforts, or the form or timing of any such outcome. The Company does not intend to make any further disclosures regarding the strategic review process unless and until a specific course of action is approved by the Company's board of directors or until the Company determines that further disclosure is appropriate.
"We are pursuing strategic options across three main areas following the recent developments that have impacted our ability to independently advance our respiratory programs," commented President and CEO Stephen Yoder. "One track is accelerating partnering discussions of PRS-220 and PRS-400. A second focal area is diligently selecting the best possible development partner and deal structure to re-initiate clinical development of cinrebafusp alfa, our former lead immuno-oncology asset, which has shown 100% ORR in five patients in a HER2+ gastric cancer trial that was discontinued for strategic reasons. Third, we will explore whether our balance sheet, position as a public company, and other assets are of strategic value to a range of third parties." Mr. Yoder continued, "While the challenges we recently experienced across our respiratory franchise have forced us to make very difficult personnel decisions, I cannot express enough gratitude to our departing colleagues for their dedication, collaborative spirit and integrity."
...
Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring
https://www.accesswire.com/768538/Pieris-Pharmaceuticals-Pro…
...
Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases and cancer, today provided a strategic update following recent events that have impacted its inhaled respiratory franchise, including AstraZeneca's discontinuation of enrollment of the Phase 2a study for elarekibep.
AstraZeneca has now informed the Company of its decision to terminate the parties' R&D collaboration agreement and hand back elarekibep along with discontinuing the remaining discovery program.
Pieris' management and board of directors have assessed several strategic options, which will include focusing on execution of new or expanded partnerships to advance its therapeutic programs, including cinrebafusp alfa (PRS-343), PRS-220 and PRS-400.
While it explores potential transactions, Pieris will prioritize capital preservation, with cash, cash equivalents and investments totaling approximately $54.9 million as of June 30, 2023. As part of its cash preservation plan, Pieris initiated a corporate restructuring that will result in a reduction of the Company's workforce by approximately 70%.
These and other cost-saving measures are expected to maximize the opportunity to pursue a range of transactions across both its respiratory and immuno-oncology franchises and its discovery platform. Pieris has retained Stifel, Nicolaus & Company, Inc. as its exclusive financial advisor to evaluate a range of strategic options.
These strategic options may include an acquisition, merger, reverse merger, other business combination, sale of assets, financing alternatives, licensing, or other strategic transactions involving the Company. There can be no assurance of a transaction, a successful outcome of these efforts, or the form or timing of any such outcome. The Company does not intend to make any further disclosures regarding the strategic review process unless and until a specific course of action is approved by the Company's board of directors or until the Company determines that further disclosure is appropriate.
"We are pursuing strategic options across three main areas following the recent developments that have impacted our ability to independently advance our respiratory programs," commented President and CEO Stephen Yoder. "One track is accelerating partnering discussions of PRS-220 and PRS-400. A second focal area is diligently selecting the best possible development partner and deal structure to re-initiate clinical development of cinrebafusp alfa, our former lead immuno-oncology asset, which has shown 100% ORR in five patients in a HER2+ gastric cancer trial that was discontinued for strategic reasons. Third, we will explore whether our balance sheet, position as a public company, and other assets are of strategic value to a range of third parties." Mr. Yoder continued, "While the challenges we recently experienced across our respiratory franchise have forced us to make very difficult personnel decisions, I cannot express enough gratitude to our departing colleagues for their dedication, collaborative spirit and integrity."
...
Pieris sollte man noch nicht abschreiben, die haben jede Menge Patente.
https://patents.justia.com/assignee/pieris-pharmaceuticals-g…
https://patents.justia.com/assignee/pieris-pharmaceuticals-g…
Antwort auf Beitrag Nr.: 74.038.473 von watchingtheflood am 21.06.23 16:12:38So ist es, muß man mit umgehen, aber das Jahr ist noch jung.
Antwort auf Beitrag Nr.: 74.037.411 von biogenetic am 21.06.23 13:56:06Man kann jetzt nicht behaupten, dass Du zuletzt vom Glück verfolgt wurdest ....
Nun ja, Biotech hat seine eigenen harten Gesetze.
Nun ja, Biotech hat seine eigenen harten Gesetze.
Durchsuchen
Pieris Pharmaceuticals
